Thursday, October 20, 2022 5:04:45 PM
Biosect,
I've seen others say we need a facility here in the U.S. by law when it comes to biological based products, I'm certainly no expert but I believe the FDA will want to see the facility duplicated here. I believe that CRL can meet that demand, but don't know if they're in the process of doing it, or waiting approval in the U.K. and perhaps a formal announcement of their relationship with NWBO to be released.
I believe CRL has multiple facilities that can be adapted to DCVax-L production with the addition of a number of the FlaskWorks units. The facilities already contain all else that is needed to support the production of the vaccine.
Probably the most important thing that people like Dr. Liau need to communicate to their colleagues is that any brain cancer patient they're operating on should have their tumors properly preserved. If they can get that message across, on approval the demand for DCVax-L could be huge as there would be a backlog of patients who potentially could benefit from its use. I really can't say what percentage of the current brain surgeons know of DCVax-L or how tumors should be preserved to make it. I believe the leukapheresis can be done just prior to making the vaccine, if I'm wrong about that, please let me know.
It's my belief that worldwide there are many facilities that could easily add a number of FlaskWorks units and could rapidly become a DCVax-L production unit. Many of these facilities may already be owned by CRL, but unless they're somehow limited, I believe the company could line up many other similar facilities to create regional distribution facilities if that was what they wished to do. I feel certain that either UCLA or City of Hope could perform such a function for all of Southern California if that was desired, and I believe there are others here that could do it as well.
Gary
I've seen others say we need a facility here in the U.S. by law when it comes to biological based products, I'm certainly no expert but I believe the FDA will want to see the facility duplicated here. I believe that CRL can meet that demand, but don't know if they're in the process of doing it, or waiting approval in the U.K. and perhaps a formal announcement of their relationship with NWBO to be released.
I believe CRL has multiple facilities that can be adapted to DCVax-L production with the addition of a number of the FlaskWorks units. The facilities already contain all else that is needed to support the production of the vaccine.
Probably the most important thing that people like Dr. Liau need to communicate to their colleagues is that any brain cancer patient they're operating on should have their tumors properly preserved. If they can get that message across, on approval the demand for DCVax-L could be huge as there would be a backlog of patients who potentially could benefit from its use. I really can't say what percentage of the current brain surgeons know of DCVax-L or how tumors should be preserved to make it. I believe the leukapheresis can be done just prior to making the vaccine, if I'm wrong about that, please let me know.
It's my belief that worldwide there are many facilities that could easily add a number of FlaskWorks units and could rapidly become a DCVax-L production unit. Many of these facilities may already be owned by CRL, but unless they're somehow limited, I believe the company could line up many other similar facilities to create regional distribution facilities if that was what they wished to do. I feel certain that either UCLA or City of Hope could perform such a function for all of Southern California if that was desired, and I believe there are others here that could do it as well.
Gary
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
